Stanford University
Showing 591-600 of 3,512 Results
-
Kyoko Sato
Associate Director, Science, Technology and Society
BioKyoko Sato is Associate Director of the Program in Science, Technology, and Society at Stanford University. Her research examines technoscientific governance in Japan and the United States. She is currently co-editing a collective volume (with Soraya Boudia and Bernadette Bensaude Vincent), Living in a Nuclear World: From Fukushima to Hiroshima, an interdisciplinary post-Fukushima reflection on the development of the global nuclear order. She has conducted fieldwork in various areas affected by nuclear technology (e.g., Fukushima, Hiroshima, Nagasaki; communities surrounding TMI, Hanford site, and other facilities; Church Rock) to examine the dynamics and relationships among global and national nuclear governance, expertise, and democratic citizenship. She is part of Comparative Covid Response, an on-going study on the pandemic response of 16 countries (led by Steve Hilgartner and Sheila Jasanoff). Her previous work examined interdisciplinary knowledge production in the United States and the politics of genetically modified food in France, Japan, and the United States. She has published in journals such as Science, Technology and Human Values; East Asian Science, Technology and Society; Theory and Society; and 科学技術社会論研究 (Journal of Science and Technology Studies; in Japanese) and book chapters on the Fukushima disaster both in English and in Japanese. She worked as a journalist in Tokyo before pursuing her PhD in sociology from Princeton University.
-
Takahiro Sato
Lead Scientist, SLAC National Accelerator Laboratory
Current Role at StanfordStaff Scientist of Material Science Department, LCLS.
Instrument lead scientist of the XPP instrument.
Principal Investigator, Stanford PULSE Institute -
Ansuman Satpathy, MD, PhD
Associate Professor of Pathology
Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
